Azithromycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Azithromycin: From Antibacterial Therapy to Hyperamylasemia
One-Sentence Summary
Azithromycin is a macrolide antibacterial that is marketed in South Africa. The TxGNN model predicts it may be effective for hyperamylasemia, with a very high score of 99.81%. However, 0 clinical trials and 0 publications support this prediction, so it rests on the model’s graph-based inference alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration records (azithromycin is a macrolide antibacterial) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Azithromycin is a macrolide antibacterial that inhibits bacterial protein synthesis by binding the 50S ribosomal subunit.
The prediction is not mechanistically supported. Hyperamylasemia is a laboratory finding (raised serum amylase), not an infectious target. The antibacterial mechanism does not explain a benefit. No pharmacological rationale linking azithromycin to this condition was identified. The high TxGNN score most likely reflects proximity in the knowledge graph rather than a real therapeutic relationship. This prediction should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 51/A20.1.1/0587 | Novazith Suspension | Suspension | Not provided in the record |
| Reg. No. A39/20.1.1/0382 | Azithromycin 500 Biotech | Tablet | Not provided in the record |
Available forms: oral tablet and suspension. Essential Medicines List (EML) status was not included in the evidence pack and has not been verified.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials, no literature and no plausible mechanism. It is an L5 (model-only) finding. Hyperamylasemia is a laboratory abnormality rather than a treatment target, so the high score alone does not justify action.
Other predictions for context: Two lower-ranked predictions have some indirect evidence and are classed as research questions, not treatment recommendations.
- Septicemic plague (L4): only in vitro susceptibility data, which reported poor azithromycin activity against Yersinia pestis strains, plus general reviews and an experimental brucellosis study. There are no human trials.
- Congenital hematological disorder (L4): the signal is limited to sickle cell disease. Two azithromycin trials (NCT02630394, NCT02960503) were both withdrawn with 0 participants enrolled, so no efficacy or safety data exist.
To proceed, the following is needed:
- The SAHPRA-approved Professional Information (warnings and contraindications) for both registered products
- Mechanism of action data (for example from DrugBank) and an expert assessment of whether any credible link to hyperamylasemia exists
- Any published clinical or preclinical evidence for azithromycin in this condition
- The approved indications for the two SAHPRA registrations, and confirmation of EML status
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.